Expression of Fas (APO-1/CD95) and Fas ligand (FasL) in human neuroblastoma

被引:0
|
作者
Gross, N [1 ]
Balmas, K
Brognara, CB
Tschopp, J
机构
[1] CHU Vaudois, Univ Hosp, Oncohematol Unit, CH-1011 Lausanne, Switzerland
[2] Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland
来源
MEDICAL AND PEDIATRIC ONCOLOGY | 2001年 / 36卷 / 01期
关键词
neuroblastoma; Fas receptor; apoptosis;
D O I
10.1002/1096-911X(20010101)36:1<111::AID-MPO1026>3.0.CO;2-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Procedure. To determine the possible role of Fas/FasL system in the particularly heterogeneous behaviour of neuroblastoma d(NB), we have measured the functional expression of Fas and its ligand, FasL, in primary neuroblastoma samples and cell lines by immunohistochemistry and flow cytometry. Results. Our results reveal that while Fas expression is associated with low stage and more mature tumors, heterogeneous FasL expression was mostly detected in high stage tumors, with-our apparent correlation to MYCN amplification. Flow cytometric analysis of cell lines demonstrated a high expression of Fas in epithelial-type, HLA class I positive cell lines, which was lost upon activation with phorbol esters. In contrast, Fas ligand was detected in only a small subset of cell lines. Conclusions. In some cell lines, cytotoxic assays revealed the ability of NB-associated Fas receptor to transduce an apoptotic signal upon triggering. The pattern of functional Fas/FasL expression in tumours and cell lines suggests that this system may be involved in the evasion of highly malignant neuroblastoma cells to host immune response. Med. Pediatr. Oncol. 36:111-114, 2001. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:111 / 114
页数:4
相关论文
共 50 条
  • [21] Expression of biologically active mouse and human CD95/APO-1/Fas ligand in the baculovirus system
    Mariani, SM
    Matiba, B
    Sparna, T
    Krammer, PH
    JOURNAL OF IMMUNOLOGICAL METHODS, 1996, 193 (01) : 63 - 70
  • [22] The CD95(APO-1/Fas) DISC and beyond
    Peter, ME
    Krammer, PH
    CELL DEATH AND DIFFERENTIATION, 2003, 10 (01): : 26 - 35
  • [23] Fas antigen/APO-1 (CD95) expression on myeloma cells
    Shima, Y
    Nishimoto, N
    Yoshizaki, K
    Kishimoto, T
    LEUKEMIA & LYMPHOMA, 1996, 23 (5-6) : 521 - +
  • [24] Fas (CD95/Apo-1) expression and apoptosis in myelodysplasia.
    Bouscary, D
    DeVos, J
    FontenayRoupie, M
    Melle, J
    Jondeau, K
    Picard, F
    Dreyfus, F
    Guesnu, M
    BLOOD, 1996, 88 (10) : 2544 - 2544
  • [25] Differential regulation of CD95 (Fas/APO-1) expression in human blood eosinophils
    Luttmann, W
    Opfer, A
    Dauer, E
    Foerster, M
    Matthys, H
    Eibel, H
    Schulze-Osthoff, K
    Kroegel, C
    Virchow, JC
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1998, 28 (07) : 2057 - 2065
  • [26] DIFFERENTIAL EXPRESSION OF APO-1 (FAS/CD95) ON HUMAN HEMATOPOIETIC-CELLS
    STAHNKE, K
    KLEIHAUER, E
    DEBATIN, KM
    EXPERIMENTAL HEMATOLOGY, 1995, 23 (08) : 888 - 888
  • [27] Mechanisms of neutrophil apoptosis in uremia and relevance of the Fas (APO-1, CD95)/Fas ligand system
    Jaber, BL
    Perianayagam, MC
    Balakrishnan, VS
    King, AJ
    Pereira, BJG
    JOURNAL OF LEUKOCYTE BIOLOGY, 2001, 69 (06) : 1006 - 1012
  • [28] Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system
    Li-Weber, M
    Krammer, PH
    SEMINARS IN IMMUNOLOGY, 2003, 15 (03) : 145 - 157
  • [29] Regulation of apoptosis through CD95 (APO-1/FAS) receptor/ligand
    Debatin, KM
    EXPERIMENTAL HEMATOLOGY, 1997, 25 (08) : 228 - 228
  • [30] Co-expression of Fas (APO-1, CD95)/Fas ligand by BeWo and NJG choriocarcinoma cell lines
    Rajashekhar, G
    Loganath, A
    Roy, AC
    Mongelli, JM
    GYNECOLOGIC ONCOLOGY, 2003, 91 (01) : 101 - 111